BACKGROUND: Neonatal germinal matrix hemorrhage/intraventricular hemorrhage is common and often results in hydrocephalus. The pathogenesis of posthemorrhagic hydrocephalus is not fully understood. OBJECTIVE: To explore the potential role of hemoglobin and iron released after hemorrhage. METHODS: Artificial cerebrospinal fluid (aCSF), hemoglobin, or iron was injected into the right lateral ventricle of postnatal day-7 Sprague Dawley rats. Ventricle size, heme oxygenase-1 (HO-1) expression, and the presence of iron were evaluated 24 and 72 hours after injection. A subset of animals was treated with an iron chelator (deferoxamine) or vehicle for 24 hours after hemoglobin injection, and ventricle size and cell death were evaluated. RESULTS: Intraventricular injection of hemoglobin and iron resulted in ventricular enlargement at 24 hours compared with the injection of aCSF. Protoporphyrin IX, the iron-deficient immediate heme precursor, did not result in ventricular enlargement after injection into the ventricle. HO-1, the enzyme that releases iron from heme, was increased in the hippocampus and cortex of hemoglobin-injected animals at 24 hours compared with aCSF-injected controls. Treatment with an iron chelator, deferoxamine, decreased hemoglobin-induced ventricular enlargement and cell death. CONCLUSION: Intraventricular injection of hemoglobin and iron can induce hydrocephalus. Treatment with an iron chelator reduced hemoglobin-induced ventricular enlargement. This has implications for the pathogenesis and treatment of posthemorrhagic hydrocephalus. ABBREVIATIONS: aCSF, artificial cerebrospinal fluidDAB, 3,3'-diaminobenzidine-4HClGMH-IVH, germinal matrix hemorrhage/intraventricular hemorrhageHO-1, heme oxygenase-1ICH, intracerebral hemorrhagePBS, phosphate-buffered salineSVZ, subventricular zoneTBST, tris-buffered saline with Tween 20.
BACKGROUND: Neonatal germinal matrix hemorrhage/intraventricular hemorrhage is common and often results in hydrocephalus. The pathogenesis of posthemorrhagic hydrocephalus is not fully understood. OBJECTIVE: To explore the potential role of hemoglobin and iron released after hemorrhage. METHODS: Artificial cerebrospinal fluid (aCSF), hemoglobin, or iron was injected into the right lateral ventricle of postnatal day-7 Sprague Dawley rats. Ventricle size, heme oxygenase-1 (HO-1) expression, and the presence of iron were evaluated 24 and 72 hours after injection. A subset of animals was treated with an iron chelator (deferoxamine) or vehicle for 24 hours after hemoglobin injection, and ventricle size and cell death were evaluated. RESULTS: Intraventricular injection of hemoglobin and iron resulted in ventricular enlargement at 24 hours compared with the injection of aCSF. Protoporphyrin IX, the iron-deficient immediate heme precursor, did not result in ventricular enlargement after injection into the ventricle. HO-1, the enzyme that releases iron from heme, was increased in the hippocampus and cortex of hemoglobin-injected animals at 24 hours compared with aCSF-injected controls. Treatment with an iron chelator, deferoxamine, decreased hemoglobin-induced ventricular enlargement and cell death. CONCLUSION: Intraventricular injection of hemoglobin and iron can induce hydrocephalus. Treatment with an iron chelator reduced hemoglobin-induced ventricular enlargement. This has implications for the pathogenesis and treatment of posthemorrhagic hydrocephalus. ABBREVIATIONS: aCSF, artificial cerebrospinal fluidDAB, 3,3'-diaminobenzidine-4HClGMH-IVH, germinal matrix hemorrhage/intraventricular hemorrhageHO-1, heme oxygenase-1ICH, intracerebral hemorrhagePBS, phosphate-buffered salineSVZ, subventricular zoneTBST, tris-buffered saline with Tween 20.
Authors: K R Wagner; Y Hua; G M de Courten-Myers; J P Broderick; R N Nishimura; S Y Lu; B E Dwyer Journal: Cell Mol Biol (Noisy-le-grand) Date: 2000-05 Impact factor: 1.770
Authors: Chao Gao; Hanjian Du; Ya Hua; Richard F Keep; Jennifer Strahle; Guohua Xi Journal: J Cereb Blood Flow Metab Date: 2014-03-26 Impact factor: 6.200
Authors: Calvin S Carter; Timothy W Vogel; Qihong Zhang; Seongjin Seo; Ruth E Swiderski; Thomas O Moninger; Martin D Cassell; Daniel R Thedens; Kim M Keppler-Noreuil; Peggy Nopoulos; Darryl Y Nishimura; Charles C Searby; Kevin Bugge; Val C Sheffield Journal: Nat Med Date: 2012-11-18 Impact factor: 53.440
Authors: Thomas Garton; Richard F Keep; D Andrew Wilkinson; Jennifer M Strahle; Ya Hua; Hugh J L Garton; Guohua Xi Journal: Transl Stroke Res Date: 2016-06-30 Impact factor: 6.829
Authors: Dewei Guo; D Andrew Wilkinson; B Gregory Thompson; Aditya S Pandey; Richard F Keep; Guohua Xi; Ya Hua Journal: Transl Stroke Res Date: 2016-11-28 Impact factor: 6.829
Authors: Kelly B Mahaney; Chandana Buddhala; Mounica Paturu; Diego Morales; David D Limbrick; Jennifer M Strahle Journal: Stroke Date: 2020-05-13 Impact factor: 7.914
Authors: Damon Klebe; Devin McBride; Paul R Krafft; Jerry J Flores; Jiping Tang; John H Zhang Journal: J Neurosci Res Date: 2019-02-21 Impact factor: 4.164
Authors: Thomas P Garton; Yangdong He; Hugh J L Garton; Richard F Keep; Guohua Xi; Jennifer M Strahle Journal: Brain Res Date: 2016-01-07 Impact factor: 3.252